# Perindopril Amlodipine for the Treatment of Hypertension

Study · id `cardio:ct-nct01556997` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01556997](<https://clinicaltrials.gov/study/NCT01556997>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01556997

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 837 participants.

## Technical summary

Registry record NCT01556997. Randomized; double masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2015-08-25.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 837 participants (enrolled count; ClinicalTrials.gov record NCT01556997, source copy `cardio:ctgov-nct01556997-2015-09-28`, retrieved 2026-10-26)
- Start date: 2012-02 (registry gives no type) (ClinicalTrials.gov record NCT01556997, source copy `cardio:ctgov-nct01556997-2015-09-28`, retrieved 2026-10-26)
- Primary completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01556997, source copy `cardio:ctgov-nct01556997-2015-09-28`, retrieved 2026-10-26)
- Completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01556997, source copy `cardio:ctgov-nct01556997-2015-09-28`, retrieved 2026-10-26)
- Results first posted: 2015-08-25 (ClinicalTrials.gov record NCT01556997, source copy `cardio:ctgov-nct01556997-2015-09-28`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01556997, source copy `cardio:ctgov-nct01556997-2015-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01556997-2015-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Perindopril Amlodipine for the Treatment of Hypertension
- Acronym: PATH
- Condition: Essential Hypertension
- Intervention (Drug): XOMA 985
- Intervention (Drug): Amlodipine Besylate
- Intervention (Drug): Perindopril Erbumine
- Lead sponsor: Symplmed Pharmaceuticals LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)

## Provenance

Content hash: 789292ef1db22dc23a23e507cb658f3348f3914804e1273295375c6e390b7c81
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
